The U.S. Food and Drug Administration (FDA) has approved a combination of Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line therapy for adults with inoperable malignant pleural mesothelioma (MPM), a rare but aggressive cancer that affects the lungs’ protective tissue lining. The FDA’s decision was announced less than six weeks after Bristol Myers Squibb, the therapies’ developer, submitted an application requesting the approval of the combo therapy for this indication. The speedy approval was made possible by the FDA’s…
You must be logged in to read/download the full post.
The post FDA Approves Opdivo-Yervoy Combo as First-Line Therapy for Inoperable Mesothelioma appeared first on BioNewsFeeds.